| P2093 | author name string | Elio F Vanin | |
| | Robert S Kerbel | |
| | Andrew M Davidoff | |
| | Amit C Nathwani | |
| | Christian J Streck | |
| | Catherine Y C Ng | |
| | Junfang Zhou | |
| | Youbin Zhang | |
| | Susan H Barton | |
| | Troy Baudino | |
| | Stephanie J Mabry | |
| P2860 | cites work | Neuropilin is a semaphorin III receptor | Q24310629 |
| | Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity | Q24561642 |
| | Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma | Q28216873 |
| | Progress in antiangiogenic gene therapy of cancer | Q30927477 |
| | Neuroblastoma: a clinical challenge and biologic puzzle | Q33366963 |
| | Orthotopic models are necessary to predict therapy of transplantable tumors in mice | Q33649321 |
| | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 |
| | Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. | Q34756781 |
| | Tumor angiogenesis and accessibility: role of vascular endothelial growth factor | Q35040013 |
| | Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications | Q35040017 |
| | The role of VEGF in normal and neoplastic hematopoiesis | Q35052515 |
| | In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects | Q35079190 |
| | Antiangiogenic gene therapy | Q36069788 |
| | Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 |
| | Current approaches to targeting cancer using antiangiogenesis therapies | Q40394125 |
| | Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy | Q40596034 |
| | Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice | Q40617700 |
| | A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth | Q40692331 |
| | Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo | Q40833199 |
| | Mechanisms and therapeutic implications of angiogenesis | Q41161800 |
| | Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant | Q41488146 |
| | Gene therapy strategies for tumor antiangiogenesis | Q41714494 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice | Q43587296 |
| | Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo | Q45872937 |
| | Gene therapy for antiangiogenesis | Q45878377 |
| | Effect of p53 status on tumor response to antiangiogenic therapy. | Q51726544 |
| | The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing | Q58376213 |
| | Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer | Q71052737 |
| | Antiangiogenic gene therapy | Q73283000 |
| | Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa | Q73595171 |
| | The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses | Q77180057 |
| | Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma | Q77347347 |
| | Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma | Q78128696 |
| P433 | issue | 2 | |
| P921 | main subject | bioavailability | Q461809 |
| | tumor angiogenesis | Q110495869 |
| P304 | page(s) | 300-310 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. | |
| P478 | volume | 11 | |